These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

119 related articles for article (PubMed ID: 36583472)

  • 1. Compassionate use of recombinant human IL-7-hyFc as a salvage treatment for restoring lymphopenia in patients with recurrent glioblastoma.
    Ahn S; Park JS; Kim H; Heo M; Sung YC; Jeun SS
    Cancer Med; 2023 Mar; 12(6):6778-6787. PubMed ID: 36583472
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Hybrid Fc-fused interleukin-7 induces an inflamed tumor microenvironment and improves the efficacy of cancer immunotherapy.
    Kim JH; Kim YM; Choi D; Jo SB; Park HW; Hong SW; Park S; Kim S; Moon S; You G; Kang YW; Park Y; Lee BH; Lee SW
    Clin Transl Immunology; 2020; 9(9):e1168. PubMed ID: 32994996
    [TBL] [Abstract][Full Text] [Related]  

  • 3. rhIL-7-hyFc and hIL-2/TCB2c combination promotes an immune-stimulatory tumor microenvironment that improves antitumor efficacy of checkpoint inhibitors.
    Lee M; Im SK; Baek S; Ji M; Kim M; Lee EJ; Ji ST; Ferrando-Martinez S; Wolfarth A; Lee JY; Kim D; Choi D
    J Immunother Cancer; 2024 Mar; 12(3):. PubMed ID: 38471713
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Salvage therapy with single agent bevacizumab for recurrent glioblastoma.
    Chamberlain MC; Johnston SK
    J Neurooncol; 2010 Jan; 96(2):259-69. PubMed ID: 19593660
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Understanding the pharmacokinetic journey of Fc-fusion protein, rhIL-7-hyFc using complementary approach of two analytical methods, accelerator mass spectrometry and ELISA.
    Kim A; Oh MS; Lee GH; Song S; Byun MS; Choi D; Yu BY; Lee H
    Antib Ther; 2024 Apr; 7(2):105-113. PubMed ID: 38566969
    [TBL] [Abstract][Full Text] [Related]  

  • 6. From lymphopenia to restoration: IL-7 immunotherapy for lymphocyte recovery in glioblastoma.
    Kim J; Choi H; Jeun SS; Ahn S
    Cancer Lett; 2024 Apr; 588():216714. PubMed ID: 38369003
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The added value of bevacizumab concomitantly administered with carboplatin versus carboplatin alone in patients with recurrent glioblastomas.
    Kaloshi G; Diamandi P; Cakani B; Brace G; Rroji A; Petrela M
    Tumori; 2015; 101(1):41-5. PubMed ID: 25702676
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Salvage therapy with single agent bendamustine for recurrent glioblastoma.
    Chamberlain MC; Johnston SK
    J Neurooncol; 2011 Dec; 105(3):523-30. PubMed ID: 21626071
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Fc-fused IL-7 provides broad antiviral effects against respiratory virus infections through IL-17A-producing pulmonary innate-like T cells.
    Kwon DI; Park S; Jeong YL; Kim YM; Min J; Lee C; Choi JA; Choi YH; Kong HJ; Choi Y; Baek S; Lee KJ; Kang YW; Jeong C; You G; Oh Y; Im SK; Song M; Kim JK; Chang J; Choi D; Lee SW
    Cell Rep Med; 2024 Jan; 5(1):101362. PubMed ID: 38232693
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A single administration of hIL-7-hyFc induces long-lasting T-cell expansion with maintained effector functions.
    Kim S; Lee SW; Koh JY; Choi D; Heo M; Chung JY; Lee BH; Yang SH; Sung YC; Lee H; Shin EC; Park SH
    Blood Adv; 2022 Dec; 6(23):6093-6107. PubMed ID: 36206199
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Association between treatment-related lymphopenia and overall survival in elderly patients with newly diagnosed glioblastoma.
    Mendez JS; Govindan A; Leong J; Gao F; Huang J; Campian JL
    J Neurooncol; 2016 Apr; 127(2):329-35. PubMed ID: 26725885
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Salvage chemotherapy with procarbazine and fotemustine combination in the treatment of temozolomide treated recurrent glioblastoma patients.
    Silvani A; Lamperti E; Gaviani P; Eoli M; Fiumani A; Salmaggi A; Falcone C; Filippini G; Botturi A; Boiardi A
    J Neurooncol; 2008 Apr; 87(2):143-51. PubMed ID: 17576523
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Role of adjuvant or salvage radiosurgery in the management of unresected residual or progressive glioblastoma multiforme in the pre-bevacizumab era.
    Niranjan A; Kano H; Iyer A; Kondziolka D; Flickinger JC; Lunsford LD
    J Neurosurg; 2015 Apr; 122(4):757-65. PubMed ID: 25594327
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The Role of a Single Angiogenesis Inhibitor in the Treatment of Recurrent Glioblastoma Multiforme: A Meta-Analysis and Systematic Review.
    Wang Y; Xing D; Zhao M; Wang J; Yang Y
    PLoS One; 2016; 11(3):e0152170. PubMed ID: 27007828
    [TBL] [Abstract][Full Text] [Related]  

  • 15. hIL-7-hyFc, A Long-Acting IL-7, Increased Absolute Lymphocyte Count in Healthy Subjects.
    Lee SW; Choi D; Heo M; Shin EC; Park SH; Kim SJ; Oh YK; Lee BH; Yang SH; Sung YC; Lee H
    Clin Transl Sci; 2020 Nov; 13(6):1161-1169. PubMed ID: 32339447
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Outcome of salvage treatment for recurrent glioblastoma.
    Kim HR; Kim KH; Kong DS; Seol HJ; Nam DH; Lim DH; Lee JI
    J Clin Neurosci; 2015 Mar; 22(3):468-73. PubMed ID: 25595963
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Clinical observation of lymphopenia in patients with newly diagnosed glioblastoma.
    Kim WJ; Dho YS; Ock CY; Kim JW; Choi SH; Lee ST; Kim IH; Kim TM; Park CK
    J Neurooncol; 2019 Jun; 143(2):321-328. PubMed ID: 30982199
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Toxicity and efficacy of lomustine and bevacizumab in recurrent glioblastoma patients.
    Jakobsen JN; Urup T; Grunnet K; Toft A; Johansen MD; Poulsen SH; Christensen IJ; Muhic A; Poulsen HS
    J Neurooncol; 2018 Apr; 137(2):439-446. PubMed ID: 29330749
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Patterns of relapse and prognosis after bevacizumab failure in recurrent glioblastoma.
    Iwamoto FM; Abrey LE; Beal K; Gutin PH; Rosenblum MK; Reuter VE; DeAngelis LM; Lassman AB
    Neurology; 2009 Oct; 73(15):1200-6. PubMed ID: 19822869
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A long-acting interleukin-7, rhIL-7-hyFc, enhances CAR T cell expansion, persistence, and anti-tumor activity.
    Kim MY; Jayasinghe R; Devenport JM; Ritchey JK; Rettig MP; O'Neal J; Staser KW; Kennerly KM; Carter AJ; Gao F; Lee BH; Cooper ML; DiPersio JF
    Nat Commun; 2022 Jun; 13(1):3296. PubMed ID: 35697686
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.